Laura Shawver PhD

Dr. Laura Shawver is President, Chief Executive Officer and director of Silverback Therapeutics, a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active and target fundamental disease pathways in cancer, fibrosis and virology. Prior to Silverback, Dr. Shawver was President and CEO of Synthorx, Inc., a company developing engineered cytokines for cancer and autoimmune disorders, from 2017 through its acquisition by Sanofi in 2020 for $2.5B. Previously, she was CEO of Cleave Biosciences and an Entrepreneur in Residence for 5AM Ventures. Earlier in her career Dr. Shawver was the CEO and Director of Phenomix Corporation and President of SUGEN, Inc. after holding various positions. She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options. In addition to Bright Peak Therapeutics, Dr. Shawver serves on the board of Silverback, Nkarta, Relay and Cleave Therapeutics (Chair). She received her Ph.D. in Pharmacology from the University of Iowa.